Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Biogen Inc. (BIIB) shares rallied 5.7% in the last trading session to close at $120.49. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

12:42 PM ESTHealth Care Biogen offers to buy out Sage Therapeutics Biogen offers to buy out Sage Therapeutics ...

Biogen Pharmachem Industries Ltd share price was down by -3.16% from the previous closing price of ₹0.95. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels ...

Sage Future, a 501(c)(3) backed by Open Philanthropy, launched an experiment earlier this month tasking four AI models in a virtual environment with raising money for charity. The models ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neuroscience and neurodegenerative diseases with a market capitalization of $17.45 billion, finds itself at a ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and ...